RESUMEN
We report the clinical and parasitological effects of a modified treatment regimen for suramin. Twenty adult males received up to 5 g (72.5 to 84.7 mg/kg) of suramin over 36 days. Detailed clinical and laboratory examinations were done before treatment and then at intervals over 2 years. Nodules were removed at 6, 13, 26 and 52 weeks for histology. Systemic tolerance was good. Anterior segment inflammation was however common and 2 patients required intervention to prevent posterior synechiae. No new posterior segment lesions developed; a rare improvement occurred in one patient with papillitis. Proteinuria, mostly mild, occurred in nearly all patients. Previously unreported renal glycosuria was documented in one patient. Microfilariae in the skin and anterior chamber did not change significantly for 5 or more weeks after which rapid reductions occurred. Ocular parasites were absent at 2 years and skin microfilariae were near zero. Peripheral blood eosinophil counts fell in parallel with those of microfilariae in the skin and anterior chamber and were normal at one and two years. These findings at 2 years may provide indirect evidence of a macrofilaricidal or a permanent chemosterilant effect on the adult worms. Nodule examination revealed an embryotoxic effect from week 6, a lethal effect on the male worms from month 3 and on the female worms from month 6 after treatment started. At one year 34% of the female worms examined were alive. Thus total doses of suramin in the range 72.5 to 84.7 mg/kg have only a modest lethal effect on the female worms. Suramin remains a restricted drug and a suitable replacement is urgently needed.
Asunto(s)
Onchocerca volvulus , Oncocercosis/tratamiento farmacológico , Suramina/uso terapéutico , Adulto , Animales , Femenino , Estudios de Seguimiento , Humanos , Masculino , Mitosis , Onchocerca volvulus/efectos de los fármacos , Onchocerca volvulus/aislamiento & purificación , Oncocercosis/sangre , Oncocercosis/fisiopatología , Oocitos/citología , Piel/parasitología , Suramina/efectos adversos , Factores de TiempoRESUMEN
566C80 is a novel hydroxynaphthoquinone with broad-spectrum anti-parasitic properties. In vitro the compound was more potent against Plasmodium falciparum than any of the established anti-malarial drugs. It had good activity against the pathogen in Aotus monkeys and was also effective in rodents infected with various drug-resistant strains of P. yoelii and P. berghei. In mice the compound showed significant activity against Toxoplasma gondii. Evaluation of the metabolic stability of 566C80 to NADPH-mediated oxidative metabolism was made using microsome preparations from a number of species including man. Unlike other quinones examined, 566C80 was shown to be inert in these assays. In Phase 1 clinical studies up to 750mg of compound were given as a single oral dose to fasted healthy male adults. This was well tolerated and the plasma drug elimination half-life was approximately 70h. In these subjects a 450mg dose gave plasma concentrations of 0.1-0.3 micrograms/ml which were achieved 1 h post-dosing and remained so for at least 7 days. Volunteers ingesting food prior to drug administration had quinone plasma levels which were significantly higher. Phase II trials are now underway to assess 566C80 for use against malaria and opportunistic infections in AIDS patients.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/complicaciones , Antiinfecciosos/metabolismo , Malaria Falciparum/tratamiento farmacológico , Naftoquinonas/metabolismo , Infecciones Oportunistas/tratamiento farmacológico , 4-Quinolonas , Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Adulto , Animales , Antiinfecciosos/farmacocinética , Antiinfecciosos/farmacología , Antimaláricos/metabolismo , Antimaláricos/farmacocinética , Antimaláricos/farmacología , Aotus trivirgatus , Atovacuona , Perros , Humanos , Malaria Falciparum/metabolismo , Masculino , Microsomas Hepáticos/metabolismo , Persona de Mediana Edad , NADP/metabolismo , Naftoquinonas/farmacocinética , Naftoquinonas/farmacología , Infecciones Oportunistas/etiología , Plasmodium/efectos de los fármacos , Ratas , Toxoplasma/efectos de los fármacosRESUMEN
The concentrations of CGP 6140 [4-nitro-4'-(N-methyl-piperazinylthiocarbonylamido)-diphenylamine] and of its N-oxide metabolite, CGP 13,231, were measured in plasma and urine after single oral dose of 100-1600 mg of CGP 6140 to 41 fasted Ghanaian patients with Onchocerca volvulus infections. The absorption of CGP 6140 was rapid and its terminal elimination half-life was about 3 h. The plasma concentrations of CGP 6140 were essentially proportional to the dose. A greater variability in plasma concentrations was apparent after the 800 and 1600 mg doses indicating a poor bioavailability of the drug administered in fasting conditions to several patients. In plasma, the concentrations of CGP 13,231 were similar to those of CGP 6140. The amount of CGP 13,231 excreted in urine was 25-40% of the dose of CGP 6140 whereas only 1.5% was excreted as unchanged drug. If a single dose of drug is used for the treatment, the plasma concentration would be maintained for 3-4 h at a high level. At 8 h, the concentration falls to about 10% of the Cmax. If sustained plasma concentrations of the drug are needed for efficacy, twice daily administration would maintain the minimum concentration at about 10% of the Cmax.
Asunto(s)
Filaricidas/farmacocinética , Oncocercosis/tratamiento farmacológico , Piperazinas/farmacocinética , Cromatografía Líquida de Alta Presión , Relación Dosis-Respuesta a Droga , Filaricidas/sangre , Filaricidas/orina , Semivida , Humanos , Masculino , Oncocercosis/sangre , Oncocercosis/orina , Piperazinas/sangre , Piperazinas/metabolismo , Piperazinas/uso terapéuticoRESUMEN
Eleven male patients from Mali with Onchocerca volvulus infections received in random order a 1200 mg single oral dose of CGP 6140 after an overnight fast and after food intake. The concentrations of CGP 6140 and of its N-oxide metabolite, CGP 13231, were measured in plasma and urine. Mean (+/- s.d.) AUC CGP 6140 values were 67.0 +/- 10.8 mumol l-1 h in fed and 22.0 +/- 17.2 mumol l-1 h in fasting patients. The mean maximum concentrations (Cmax) in plasma +/- s.d. were 12.7 +/- 2.8 mumol l-1 in fed and 4.7 +/- 4.1 mumol l-1 in fasting patients. The median time to Cmax was 3 h in fed and 2 h in fasting patients. Mean (+/- s.d.) AUC of the N-oxide metabolite was 59.9 +/- 10.7 mumol l-1 h in fed and 23.4 +/- 16.2 mumol l-1 h in fasting patients. The urinary recovery was less than 0.5% of dose for CGP 6140 in both fed and fasting conditions. It was 30.1 +/- 11.5 and 11.4 +/- 8.0% of the dose for the N-oxide metabolite in fed and fasting conditions, respectively. Variability in plasma concentrations and urinary recovery of CGP 6140 and of the N-oxide metabolite was greater in fasted patients. The low solubility of CGP 6140 in aqueous solutions at neutral pH and its higher solubility at acidic pH might explain the increase in bioavailability after food intake. The administration of CGP 6140 after food intake is therefore recommended for an optimal systemic effect.
Asunto(s)
Filaricidas/farmacocinética , Alimentos , Oncocercosis/tratamiento farmacológico , Piperazinas/farmacocinética , Administración Oral , Disponibilidad Biológica , Filaricidas/administración & dosificación , Filaricidas/antagonistas & inhibidores , Filaricidas/uso terapéutico , Humanos , Masculino , Piperazinas/administración & dosificación , Piperazinas/antagonistas & inhibidores , Piperazinas/sangre , Piperazinas/uso terapéutico , Piperazinas/orinaAsunto(s)
Antihelmínticos , Filariasis/tratamiento farmacológico , Filaricidas , Animales , Antihelmínticos/clasificación , Antihelmínticos/farmacología , Filaricidas/clasificación , Filaricidas/farmacología , Humanos , Microfilarias/efectos de los fármacos , Microfilarias/fisiología , Tecnología FarmacéuticaRESUMEN
Novel hydroxynaphthoquinones are reported with outstanding efficacy against Plasmodium, Eimeria and Theileria species. Biochemical evidence is presented for the selective toxicity of these compounds being due to inhibition of parasite respiratory systems.
Asunto(s)
Antiprotozoarios/farmacología , Apicomplexa/efectos de los fármacos , Malaria/tratamiento farmacológico , Naftoquinonas/farmacología , Infecciones por Protozoos/tratamiento farmacológico , Animales , Antiprotozoarios/uso terapéutico , Bovinos , Pollos/parasitología , Coccidiosis/tratamiento farmacológico , Eimeria/efectos de los fármacos , Ratones , Naftoquinonas/uso terapéutico , Plasmodium berghei/efectos de los fármacos , Plasmodium falciparum/efectos de los fármacos , Theileriosis/tratamiento farmacológico , Toxoplasma/efectos de los fármacos , Toxoplasmosis Animal/tratamiento farmacológicoRESUMEN
Pyrimidine metabolism in Trichomonas vaginalis was investigated using washed cell suspensions of the organism with radiolabelled pyrimidine ring precursors and preformed pyrimidines. The precursors [14C]orotate, [14C]bicarbonate and [14C]aspartate were not incorporated into the pyrimidine bases of trichomonal nucleic acids, indicating that the protozoan is unable to synthesise the pyrimidine ring and is dependent on the salvage of exogenous pyrimidines. [3H]uracil, [3H]uridine, [3H]cytidine, deoxy[3H]cytidine and [3H]thymidine were all efficiently salvaged, and interconversion between cytosine and uracil nucleotides was detected. Thymidylate synthase activity was not detected, suggesting that T. vaginalis is dependent upon an exogenous supply of thymidine for TMP synthesis.
Asunto(s)
Pirimidinas/metabolismo , Trichomonas vaginalis/metabolismo , Animales , Ácido Aspártico/metabolismo , Bicarbonatos/metabolismo , Nucleótidos de Citosina/metabolismo , Ácido Orótico/metabolismo , Timidina/metabolismo , Timidilato Sintasa/metabolismo , Nucleótidos de Uracilo/metabolismoAsunto(s)
Purinas/metabolismo , Trichomonas vaginalis/metabolismo , Adenina/metabolismo , Nucleótidos de Adenina/metabolismo , Adenosina Monofosfato/metabolismo , Animales , Guanina/metabolismo , Nucleótidos de Guanina/metabolismo , Guanosina/metabolismo , Nucleósido-Fosfato Quinasa/metabolismo , Purina-Nucleósido Fosforilasa/metabolismoRESUMEN
The activities of carbamoylphosphate synthase, aspartate transcarbamoylase, dihydroorotase, orotate phosphoribosyl transferase and orotidine-5'-phosphate decarboxylase, five of the six enzymes of pyrimidine biosynthesis, have been measured in Crithidia fasciculata, Trypanosoma cruzi, Leishmania major, Trichomonas vaginalis, Eimeria tenella, Toxoplasma gondii, Plasmodium berghei, Fasciola gigantica, Schistosoma mansoni, Hymenolepis diminuta, Nippostrongylus brasiliensis and Trichuris muris. The majority of organisms contained all five enzyme activities. However, in T. vaginalis only carbamoylphosphate synthetase activity and in E. tenella only orotate phosphoribosyl transferase and orotidine-5'-phosphate decarboxylase activities could be detected. It appears therefore that the ability to synthesise pyrimidines by the de novo route is probably both common and widespread amongst parasitic organisms.